Technology

BRCA Testing – Making Treatment Decisions Today and Planning for the Future

The ubiquity of the pink ribbon campaign, the prevalence of precision medicine as a recurring theme in every scientific and medical journal, and the very fact that BRCA has entered the lexicon of society – globally – suggests that breast cancer testing is standard. Indeed, something that has been part of everyday life for some… Read article →


QIAGEN at NGS Bioinformatics Challenge in Germany

QIAGEN had the pleasure of taking part in an NGS Bioinformatics Challenge run by the German Society for Pathology on the 9th and 10th of November in Halle, Germany. Three commercial organizations were supplied with vcf files from twelve samples sequenced using Illumina MiSeq™ Systems and the IonTorrent platform at Erlangen, Cologne Berlin. The identity… Read article →


PART 1: The Role of NGS in Myeloid Leukemia

Myeloid malignancies are complex clonal diseases arising in hematopoietic stem or progenitor cells. These heterogenous disorders comprise many different subtypes such as myeloproliferative neoplasms (MPN), myelodysplastic syndrome (MDS), myelodysplastic/myeloproliferative neoplasms (MDS/MPN) and acute myeloid leukemia (AML). There is a growing need for molecular profiling of these blood and bone marrow disorders to provide better definition… Read article →


NGS is helping oncologists make informed treatment decisions

For decades, tissue-conserving surgery coupled with chemotherapy (either preceding or following surgery, depending on the size of the tumor(s)) followed by radiation has been the standard of care for the majority of cancers. Over the past fifteen years, chemoradiotherapy (concurrently dosing a patient with chemotherapy and radiation) has improved the overall survival rates especially for… Read article →



AMP Europe 2018

Watch Dr. Atil Bisgil from Cukurova University, Turkey talk about expanding to microbiome research with the GeneReader NGS System. He discusses the pressures faced in a laboratory focused on next generation sequencing and research, looking toward the future of high-throughput NGS testing and expanding to microbiome research with the GeneReader.  



QIAGEN receives FDA clearance for first-ever JAK2 test for use in diagnosis of additional myeloproliferative neoplasms

Expanded use of ipsogen test provides diagnostic testing needs for all myeloproliferative neoplasms in line with the latest WHO guidelines Hilden, Germany, and Germantown, Maryland, January 23, 2018 – QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has received clearance for its ipsogen JAK2 RGQ PCR Kit (ipsogen JAK2 assay) from the… Read article →




QIAGEN launches first FDA-cleared JAK2 test for certain type of leukemia

New biomarker test – the fifth QIAGEN oncology test with FDA clearance in the U.S. – designed to aid diagnosis of patients suspected of having Polycythemia Vera form of blood cancer Germantown, Maryland, and Hilden, Germany, March 29, 2017 – QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced the U.S. launch of its ipsogen® JAK2 RGQ… Read article →



QIAGEN launches unique CALR mutation assay for MPN diagnosis

European launch of the new CE marked ipsogen CALR RGQ PCR Kit to improve MPN diagnosis for leukemia patients in line with latest WHO recommendations and clinical guidelines HILDEN, Germany, Dec. 1, 2016 – QIAGEN today announced the European launch of a unique CE-IVD marked calreticulin (CALR) mutation assay to aid in establishing the diagnosis… Read article →


QIAGEN GeneReader NGS System to relaunch in U.S. market

New improved chemistry for first Sample to Insight next-generation sequencing solution to be made available to first customers in December 2016 Charlotte, North Carolina, and Hilden, Germany, November 9, 2016 – QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced the validation of new and improved sequencing  chemistry for its GeneReader NGS System, the… Read article →


WT1 expression and NPM1 mutations as biomarkers for minimal residual disease (MRD) monitoring in AML patients

The AML Global Portal highlights the value of AML biomarkers WT1 expression and NPM1 mutation for MRD monitoring in AML patients The AML_Global_Portal is an evidence-based online resource committed to informing and educating health care providers about the latest cutting-edge advancements in acute myeloid leukemia (AML). The portal aims to help advance understanding and share… Read article →


Infographic: Filtering the flood

The global DNA sequencing capacity is increasing 3x-5x per year, leading to an unprecedented flood of biological data. Already, the output of biological data amounts to 15 petabytes a year (the equivalent of >3 million DVDs) and its amount doubles every 9 months, making it hard for scientists to keep up and put the information… Read article →